Search our Database of Scientific Publications and Authors

I’m looking for a

    9619 results match your criteria Acromegaly

    1 OF 193

    Endocr Pract 2017 Feb 22. Epub 2017 Feb 22.
    From: 1Endocrinology Service/Experimental Endocrinology Unit.
    Background: Acromegaly is associated with an increased risk of colonic polyps. The magnitude of such risk is controversial and the characteristics that distinguish patients who develop polyps from those who do not are not well established.

    Objective: To determine the prevalence of colonic polyps upon the diagnosis of acromegaly. Read More

    Aırway and sleep dısorders ın patıents wıth acromegaly.
    Clin Respir J 2017 Feb 22. Epub 2017 Feb 22.
    Dokuz Eylul University, Division of Endocrinology and Metabolism, Izmir, TURKEY.
    Introduction-objective: Acromegaly is a multisystemic disorder caused by excessive secretion of growth hormone (GH). Sleep-disordered breathing (SDB) such as sleep apnea syndrome (SAS) may occur in acromegaly. The aim of study was to assess the presence of sleep disorders and evaluate the systemic complications on respiratory, cardiovascular and upper airway systems in acromegalic patients. Read More

    Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.
    Pituitary 2017 Feb 21. Epub 2017 Feb 21.
    Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, via S. Pansini 5, 80131, Naples, Italy.
    Acromegaly is associated with an enhanced mortality, with cardiovascular and respiratory complications representing not only the most frequent comorbidities but also two of the main causes of deaths, whereas a minor role is played by metabolic complications, and particularly diabetes mellitus. The most prevalent cardiovascular complications of acromegaly include a cardiomyopathy, characterized by cardiac hypertrophy and diastolic and systolic dysfunction together with arterial hypertension, cardiac rhythm disorders and valve diseases, as well as vascular endothelial dysfunction. Biochemical control of acromegaly significantly improves cardiovascular disease, albeit completely recovering to normal mainly in young patients with short disease duration. Read More

    Two-dimensional speckle tracking echocardiography demonstrates no effect of active acromegaly on left ventricular strain.
    Pituitary 2017 Feb 20. Epub 2017 Feb 20.
    Neuroendocrinology Research Center/ Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
    Background: Speckle tracking echocardiography (STE) allows for the study of myocardial strain (ε), a marker of early and subclinical ventricular systolic dysfunction. Cardiac disease may be present in patients with acromegaly; however, STE has never been used to evaluate these patients.

    Objective: To evaluate left ventricular (LV) global longitudinal strain in patients with active acromegaly with normal LV systolic function. Read More

    Computed tomography airway lumen volumetry in patients with acromegaly: Association with growth hormone levels and lung function.
    J Med Imaging Radiat Oncol 2017 Feb 19. Epub 2017 Feb 19.
    Postgraduate Programme in Medical Sciences, School of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro, Brazil.
    Introduction: The segmentation and skeletonisation of images via computed tomography (CT) airway lumen volumetry provide a new perspective regarding the incorporation of this technique in medical practice. Our aim was to quantify morphological changes in the large airways of patients with acromegaly through CT and, secondarily, to correlate these findings with hormone levels and pulmonary function testing (PFT) parameters.

    Methods: This was a cross-sectional study in which 28 non-smoker patients with acromegaly and 15 control subjects underwent CT analysis of airway lumen volumetry with subsequent image segmentation and skeletonisation. Read More

    Therapeutic use of hormones on tendinopathies: a narrative review.
    Muscles Ligaments Tendons J 2016 Oct-Dec;6(4):445-452. Epub 2016 Feb 12.
    Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti - Pescara, Chieti, Italy.
    Background: Hormones can modify tendon homeostasis, some of them leading to tendon damage, while others are essentials for healing. This narrative review summarizes the current knowledge on the topic, focusing on the hormones normally secreted by endocrine glands.

    Methods: A search in PubMed, Web of Knowledge and EMBASE, using the terms tendinopathy or tendon, combined with estrogens, testosterone, thyroid and parathyroid hormones, glucocorticoids and growth hormone, independently, was performed. Read More

    Updates in outcomes of stereotactic radiation therapy in acromegaly.
    Pituitary 2017 Feb 16. Epub 2017 Feb 16.
    C.I. Parhon" National Institute of Endocrinology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
    Purpose Treatment of acromegaly has undergone important progress in the last 20 years mainly due to the development of new medical options and advances in surgical techniques. Pituitary surgery is usually first-line therapy, and medical treatment is indicated for persistent disease, while radiation (RT) is often used as third-line therapy. The benefits of RT (tumor volume control and decreased hormonal secretion) are hampered by the long latency of the effect and the high risk of adverse effects. Read More

    Diagnostic challenges and management of a patient with acromegaly due to ectopic growth hormone-releasing hormone secretion from a bronchial carcinoid tumour.
    Endocrinol Diabetes Metab Case Rep 2017 6;2017. Epub 2017 Jan 6.
    Leeds Centre for Diabetes and Endocrinology , St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds , UK.
    : A male patient presented at the age of 30 with classic clinical features of acromegaly and was found to have elevated growth hormone levels, not suppressing during an oral glucose tolerance test. His acromegaly was originally considered to be of pituitary origin, based on a CT scan, which was interpreted as showing a pituitary macroadenoma. Despite two trans-sphenoidal surgeries, cranial radiotherapy and periods of treatment with bromocriptine and octreotide, his acromegaly remained active clinically and biochemically. Read More

    T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective.
    Pituitary 2017 Feb 14. Epub 2017 Feb 14.
    Department of Endocrinology, Centre Hospitalier Universitaire de Liège, Université de Liège, Domaine Universitaire du Sart-Tilman, 4000, Liège, Belgium.
    T2-weighted MRI signal intensity of GH-secreting pituitary adenomas is gaining recognition as a marker of disease characteristics and may be a predictor of response to treatment of acromegaly. Adenomas that are T2-hypointense are more common, are smaller and are less likely to invade the cavernous sinus compared to the T2-iso and hyperintense tumors. T2-hypointense tumors are also accompanied by higher IGF1 values at baseline. Read More

    The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gsp(-) somatotropinomas.
    Eur J Endocrinol 2017 Feb 8. Epub 2017 Feb 8.
    G Occhi, Department of Biology, University of Padua, Padova, Italy
    Objective: Glucose-dependent insulinotropic polypeptide receptor (GIPR) overexpression has been recently described in a proportion of gsp(-) somatotropinomas and suggested to be associated with the paradoxical increase of GH (GH-PI) during an oral glucose load. Design and Methods: This study was aimed at linking the GIP/GIPR pathway to GH secretion in 25 somatotropinomas-derived primary cultures and correlating molecular with clinical features in acromegalic patients. Given the impairment of the GIPR/GIPR axis in acromegaly, an additional aim was to assess the effect of GH/IGF-1 stimulation on GIP expression in the enteroendocrine cell line STC-1. Read More

    Pegvisomant in acromegaly: an update.
    J Endocrinol Invest 2017 Feb 7. Epub 2017 Feb 7.
    Department of Medical Sciences, School of Medicine, University of Turin, Turin, Italy.
    Background: In 2007, we published an opinion document to review the role of pegvisomant (PEG) in the treatment of acromegaly. Since then, new evidence emerged on the biochemical and clinical effects of PEG and on its long-term efficacy and safety.

    Aim: We here reviewed the emerging aspects of the use of PEG in clinical practice in the light of the most recent literature. Read More

    Somatostatin receptor ligands in the treatment of acromegaly.
    Pituitary 2017 Feb 7. Epub 2017 Feb 7.
    Endocrinology Unit, Department of Internal Medicine and Medical Specialties and Center of Excellence for Biomedical Research, University of Genoa, Genoa, Italy.
    First-generation somatostatin receptors ligands (SRL) are the mainstay in the medical treatment of acromegaly, however the percentage of patients controlled with these drugs significantly varies in the different studies. Many factors are involved in the resistance to SRL. In this review, we update the physiology of somatostatin and its receptors (sst), the use of SRL in the treatment of acromegaly and the factors involved in the response to these drugs. Read More

    Biochemical investigations in diagnosis and follow up of acromegaly.
    Pituitary 2017 Feb 6. Epub 2017 Feb 6.
    Endocrine Laboratory, Endocrine Research Unit, Medizinische Klinik und Poliklinik IV, Klinikum der Ludwig-Maximilians-Universität (LMU), Ziemssenstr. 1, 80336, Munich, Germany.
    Measurements of human growth hormone (GH) and insulin-like growth-factor I (IGF-I) are cornerstones in the diagnosis of acromegaly. Both hormones are also used as biochemical markers in the evaluation of disease activity during treatment. Management of acromegaly is particularly challenging in cases where discordant information is obtained from measurement of GH concentrations following oral glucose load and from measurement of IGF-I. Read More

    Renin-Angiotensin System Blockade Improves Cardiac Indices in Acromegaly Patients.
    Exp Clin Endocrinol Diabetes 2017 Feb 6. Epub 2017 Feb 6.
    Centre for Endocrinology, WHRI, Barts & the London School of Medicine and Dentistry, Queen Mary University of London.
    Blockade of the angiotensin-renin system, with angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs), has been shown to improve cardiac outcomes following myocardial infarction and delay progression of heart failure. Acromegaly is associated with a disease-specific cardiomyopathy, the pathogenesis of which is poorly understood.The cardiac indices of patients with active acromegaly with no hypertension (Group A, n=4), established hypertension not taking ACEi/ARBs (Group B, n=4) and established hypertension taking ACEi/ARBs (Group C, n=4) were compared using cardiac magnetic imaging. Read More

    Assessment of Mean Platelet Volume and its Effect on Disease Control in Patients with Acromegaly.
    Clin Lab 2016 Nov;62(11):2167-2171
    Background: Morbidity and mortality rates due to cardiovascular diseases are more common in acromegalic patients than the healthy population. Platelets play a significant role in both the onset and progression of clotting which then cause the development of atherosclerotic plaques. Increased mean platelet volume (MPV) is an indicator of platelet activation and known as an independent risk factor for atherosclerotic processes. Read More

    The genetic background of acromegaly.
    Pituitary 2017 Feb 4. Epub 2017 Feb 4.
    Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, Charterhouse Square, London, EC1A 6BQ, UK.
    Acromegaly is caused by a somatotropinoma in the vast majority of the cases. These are monoclonal tumors that can occur sporadically or rarely in a familial setting. In the last few years, novel familial syndromes have been described and recent studies explored the landscape of somatic mutations in sporadic somatotropinomas. Read More

    Endocr Pract 2017 Feb 3. Epub 2017 Feb 3.
    Akdeniz University, School of Medicine, Division of Endocrinology and Metabolism, Antalya, Turkey.
    Objective: Early diagnosis and treatment of cardiovascular diseases, the most frequent cause of morbidity and mortality in acromegaly, may be an efficient approach to extending the lifespan of the affected patients. Therefore, it is crucial to determine any cardiovascular diseases in the subclinical period. The study objectives were to determine markers of subclinical atherosclerosis and asses heart structure and functioning. Read More

    Diabetes in Patients With Acromegaly.
    Curr Diab Rep 2017 Feb;17(2)
    Department of Endocrinology, Adelaide and Meath Hospitals incorporating the National Children's Hospital and Trinity College Dublin, Tallaght, Dublin 24, Ireland.
    Purpose Of Review: Acromegaly is a clinical syndrome which results from growth hormone excess. Uncontrolled acromegaly is associated with cardiovascular mortality, due to an excess of risk factors including diabetes mellitus, hypertension and cardiomegaly. Diabetes mellitus is a frequent complication of acromegaly with a prevalence of 12-37%. Read More

    Pasireotide Long-Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism.
    J Vet Intern Med 2017 Feb 1. Epub 2017 Feb 1.
    Diabetic Remission Clinic, Department of Clinical Science and Services, Royal Veterinary College, Hertfordshire, UK.
    Background: Long-term medical management of hypersomatotropism (HS) in cats has proved unrewarding. Pasireotide, a novel somatostatin analogue, decreases serum insulin-like growth factor 1 (IGF-1) and improves insulin sensitivity in cats with HS when administered as a short-acting preparation.

    Objectives: Assess once-monthly administration of long-acting pasireotide (pasireotide LAR) for treatment of cats with HS. Read More

    The evaluation of central corneal thickness and intraocular pressure in conjunction with tear IGF-1 levels in patients with acromegaly.
    Eur J Ophthalmol 2017 Jan 27. Epub 2017 Jan 27.
    Department of Biochemistry, School of Medicine, Ondokuz Mayıs University, Samsun - Turkey.
    Purpose: To compare the central corneal thickness (CCT), intraocular pressure (IOP), and tear insulin-like growth factor 1 (IGF-1) levels between patients with acromegaly and a control group and to evaluate the possible effect of tear IGF-1 and duration of the disease on CCT and IOP.

    Methods: We included 31 patients with acromegaly (study group) and 40 age- and sex-matched controls in the study. Patients with acromegaly were divided into 2 subgroups based on disease status (active/inactive). Read More

    Pituitary acromegaly: not one disease.
    Endocr Relat Cancer 2017 Jan 25. Epub 2017 Jan 25.
    S Ezzat, Medicine, University of Toronto, Toronto, Canada.
    Acromegaly has traditionally been regarded as a monomorphous disorder resulting from a benign pituitary adenoma. Increasing evidence, however, is highlighting that this disorder is associated with a spectrum of morphologically distinct pituitary tumors with variable clinical, biochemical and radiologic features and differing therapeutic outcomes that are attributed to different genetic and epigenetic changes. These data underscore the need for developing a more refined clinicopathological risk stratification system and implementing personalized targeted therapeutic approaches. Read More

    Feline hypersomatotropism and acromegaly tumorigenesis: a potential role for the AIP gene.
    Domest Anim Endocrinol 2016 Dec 8;59:134-139. Epub 2016 Dec 8.
    Clinical Science and Services, Royal Veterinary College, Hawkshead Lane, North Mymms, Hertfordshire AL9 7TA, UK.
    Acromegaly in humans is usually sporadic, however up to 20% of familial isolated pituitary adenomas are caused by germline sequence variants of the aryl-hydrocarbon-receptor interacting protein (AIP) gene. Feline acromegaly has similarities to human acromegalic families with AIP mutations. The aim of this study was to sequence the feline AIP gene, identify sequence variants and compare the AIP gene sequence between feline acromegalic and control cats, and in acromegalic siblings. Read More

    Relationship between expression of vascular endothelial growth factor and the proliferation of prolactinomas.
    Clin Neurol Neurosurg 2017 Feb 14;153:102-106. Epub 2016 Dec 14.
    The First Affiliated Hospital of BengBu Medical College, Department of Neurosurgery, China. Electronic address:
    Objective: Prolactinomas are the most common functional hormone-producing pituitary lesions, accounting for 30-40% of all pituitary tumors, while in autopsy series their incidence reaches 50%. However, patients with prolactinoma had a higher recurrence percentage and rate than patients with acromegaly or Cushing's disease. Furthermore, prolactinomas have the highest rate of recurrence post-surgery as compared with other pituitary adenomas. Read More

    A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues.
    Eur J Endocrinol 2017 Apr 18;176(4):421-430. Epub 2017 Jan 18.
    Department of Internal MedicineEndocrinology Section, Erasmus University Medical Center, Rotterdam, The Netherlands.
    Background: Effective treatment of acromegaly with pegvisomant (PEGV), a growth hormone receptor antagonist, requires an appropriate dose titration. PEGV doses vary widely among individual patients, and various covariates may affect its dosing and pharmacokinetics.

    Objective: To identify predictors of the PEGV dose required to normalize insulin-like growth factor I (IGF-I) levels during PEGV monotherapy and in combination with long-acting somatostatin analogues (LA-SSAs). Read More

    Endocr Pract 2017 Jan 17. Epub 2017 Jan 17.
    Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936.
    Objective: Data mining using insurance claims presents an opportunity to incorporate new analytic techniques in identifying rare conditions. This study aims to identify dyads of clinical conditions associated with acromegaly that may, with further validation and testing, be used to initially identify and diagnose this rare disease more accurately and efficiently.

    Methods: This case-control study used two claims databases to identify acromegaly patients (cases) (ICD-9-CM: 253. Read More

    New medical therapies on the horizon: oral octreotide.
    Pituitary 2017 Jan 16. Epub 2017 Jan 16.
    Division of Endocrinology, Department of Internal Medicine, Leiden University Medical Center, BOX 9600, 2300, RC Leiden, The Netherlands.
    Somatostatin analog treatment is first line medical treatment in patients with acromegaly. This drug is currently mainly administered by monthly depot preparations of octreotide and lanreotide. With the innovative transient permeability enhancer, a technology enabling the absorption of drug molecules via transient opening of the tight junctions of the gut epithelium, it is possible to achieve therapeutic octreotide levels after oral ingestion. Read More

    Delayed CSF Rhinorrhea after Gamma Knife Radiosurgery with or without Preceding Transsphenoidal Resection for Pituitary Pathology.
    World Neurosurg 2017 Jan 9. Epub 2017 Jan 9.
    Department of Neurologic Surgery, Mayo Clinic, Rochester MN; Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester MN. Electronic address:
    Background: Skull base cerebrospinal fluid (CSF) leak after gamma knife radiosurgery (GKRS) is a very rare complication. In patients who were treated with both GKRS and transsphenoidal resection (TSR) for pituitary lesions, early CSF leak occurs at a comparable rate to the general TSR population (4%). Delayed CSF leak occurring more than a year after TSR, GKRS, or dual therapy, is exceedingly rare. Read More

    Mixed Gangliocytoma-Pituitary Adenoma: Insights on the Pathogenesis of a Rare Sellar Tumor.
    Am J Surg Pathol 2017 Jan 10. Epub 2017 Jan 10.
    Department of Pathology, University of Virginia School of Medicine, Charlottesville, VA.
    Gangliocytomas originating in the sellar region are rare; most are tumors composed of gangliocytic and pituitary adenomatous elements, forming the so-called mixed gangliocytoma-pituitary adenoma. The majority of mixed gangliocytoma adenomas are associated with endocrinopathies, mainly acromegaly and less often Cushing disease and hyperprolactinemia. In the present study, 10 cases of mixed gangliocytoma and somatotroph adenomas were evaluated for patterns of cellular differentiation and expression of lineage-specific transcription factors. Read More

    Bone material strength index as measured by impact microindentation is altered in patients with acromegaly.
    Eur J Endocrinol 2017 Mar 11;176(3):339-347. Epub 2017 Jan 11.
    Centre for Bone Quality, Division Endocrinology
    Objective: Acromegaly is a rare disease caused by excess growth hormone (GH) production by the pituitary adenoma. The skeletal complications of GH and IGF-1 excess include increased bone turnover, increased cortical bone mass and deteriorated microarchitecture of trabecular bone, associated with a high risk of vertebral fractures in the presence of relatively normal bone mineral density (BMD). We aimed to evaluate tissue-level properties of bone using impact microindentation (IMI) in well-controlled patients with acromegaly aged ≥18 years compared to 44 controls from the outpatient clinic of the Centre for Bone Quality. Read More

    Assessment of Nasal Carriage of Staphylococcus Aureus and Axillar Flora in Patients With Acromegaly.
    J Craniofac Surg 2017 Jan 5. Epub 2017 Jan 5.
    *Department of Endocrinology and Metabolism †Department of Infection Disaese, School of Medicine, Mersin University, Yenişehir, Mersin, Turkey.
    Purpose: Recent study showed that patients with acromegaly have typical skin findings including increased sebum secretion, decreased transepidermal water loss, more alkaline, and colder skin surface correlated with serum growth hormone and insulin-like growth factor 1 levels. Different anatomic localizations and texture of the skin differ in bacterial concentrations.Nasal carriage of Staphylococcus aureus and axillar flora in patients with acromegaly was compared with normal population with regard to duration of acromegaly as well as the growth hormone and insulin-like growth factor 1 levels. Read More

    Patient satisfaction and preferences of lanreotide Autogel treatment in acromegaly.
    Endokrynol Pol 2016 ;67(6):572-579
    Department of Endocrinology and Isotope Therapy, Military Institute of Medicine, Warsaw, Poland.
    Introduction: Despite the known importance of somatostatin analogues (SSAs) in the treatment of acromegaly, patient satisfaction leading to preferences for specific SSAs have received little attention so far.

    Material And Methods: This open, prospective, observational, multicentre patient-reported outcome study included adult patients with acromegaly, who switched from another SSA to lanreotide Autogel (new and previous devices) at least two months prior to enrolment. The observation period was around 12 months. Read More

    Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management.
    Endocrine 2017 Feb 2;55(2):346-359. Epub 2017 Jan 2.
    Department of Endocrinology, Hospital Universitario La Princesa, Instituto de Investigación Princesa, Universidad Autónoma, Madrid, Spain.
    Comorbidities related to the cardiovascular system are one of the most prevalent in patients with acromegaly, and contribute to an increased risk of morbidity and all-cause mortality. Specifically, hypertension, cardiomyopathy, heart valve disease, arrhythmias, atherosclerosis, coronary artery disease, and cardiac dysfunction may be frequent findings. Although the underlying physiopathology for each comorbidity may not be fully elucidated, uncontrolled growth hormone/insulin-like growth factor 1 excess, age, prolonged disease duration, and coexistence of other cardio-vascular risk factors are significant influencing variables. Read More

    Auditory changes in acromegaly.
    J Endocrinol Invest 2016 Dec 29. Epub 2016 Dec 29.
    Division of Endocrinology and Diabetes, Department of Internal Medicine, Gaziantep University Medical Faculty, Gaziantep, Turkey.
    Objective: The aim of this study is to determine the changes involving auditory system in cases with acromegaly.

    Materials And Methods: Otological examinations of 41 cases with acromegaly (uncontrolled n = 22, controlled n = 19) were compared with those of age and gender-matched 24 healthy subjects. Whereas the cases with acromegaly underwent examination with pure tone audiometry (PTA), speech audiometry for speech discrimination (SD), tympanometry, stapedius reflex evaluation and otoacoustic emission tests, the control group did only have otological examination and PTA. Read More

    Cabergoline in acromegaly.
    Pituitary 2016 Dec 26. Epub 2016 Dec 26.
    Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre Service d'Endocrinologie et des Maladies de la Reproduction, 78 rue du Général Leclerc, 94275, Le Kremlin-Bicêtre, France.
    Acromegaly, a rare disease due to growth hormone (GH) hypersecretion by a pituitary adenoma, is associated with severe comorbidity and premature death if not adequately treated. The usual first-line treatment is surgery. Various drugs, including somatostatin receptor ligands, dopamine agonists and GH receptor antagonists, are now available for use if surgery fails to suppress GH/IGF-I hypersecretion. Read More

    Remission of acromegaly after treatment withdrawal in patients controlled by cabergoline alone or in combination with octreotide: results from a multicenter study.
    J Endocrinol Invest 2016 Dec 23. Epub 2016 Dec 23.
    Neuroendocrine Unit, Division of Endocrinology and Metabolism, Universidade Federal de São Paulo, Rua Botucatu, 806, Vila Clementino, São Paulo, SP, CEP 04023-062, Brazil.
    Purpose: Remission of acromegaly has been reported after somatostatin analogs withdrawal, but not after withdrawal of combination therapy with cabergoline, and only in case reports of patients controlled by cabergoline alone.

    Methods: To establish the remission rates (normal IGF-1 for age/sex: IGF-1 ≤ 1.00 xULN) after withdrawal of combined treatment with octreotide LAR and cabergoline and of cabergoline alone, we prospectively studied 16 patients with acromegaly controlled by those treatments in the preceding 2 years as part of a larger study on remission of acromegaly after withdrawal of different medical treatments. Read More

    Communication practices and awareness of resources for acromegaly patients among endocrinologists.
    Patient Prefer Adherence 2016 14;10:2531-2541. Epub 2016 Dec 14.
    Department of Internal Medicine, Metabolism Endocrinology & Diabetes (MEND), University of Michigan, Ann Arbor, MI, USA.
    Purpose: This study was designed to assess the awareness and utilization of resources to improve patients' treatment experiences among endocrinologists who currently treat patients with acromegaly.

    Methods: A total of 4,280 US endocrinologists were randomly selected from the CMS National Plan and Provider Enumeration System and were invited by mail to participate in a 20-minute online survey. In order to qualify, respondents had to be the primary physician making treatment decisions for at least one patient for their acromegaly. Read More

    Clinical characteristics and management of growth hormone excess in patients with McCune-Albright syndrome.
    Eur J Endocrinol 2017 Mar 22;176(3):295-303. Epub 2016 Dec 22.
    Key Laboratory of Endocrinology of National Health and Family Planning CommissionDepartment of Endocrinology
    Objective: McCune-Albright syndrome (MAS) is a sporadic, postzygotic disease presenting with fibrous dysplasia, cafe-au-lait spots and multiple endocrinopathies. Growth hormone (GH) excess is an uncommon but potentially severe complication of MAS. This study aims to describe the clinical manifestations of GH excess in the context of MAS and analyze the responses of these patients to treatments. Read More

    Hypertension: The role of biochemistry in the diagnosis and management.
    Clin Chim Acta 2017 Feb 19;465:131-143. Epub 2016 Dec 19.
    Dept. of Clinical Biochemistry & Diagnostic Endocrinology, Mater Misericordiae University Hospital, Dublin, Ireland.
    Hypertension is defined as a persistently elevated blood pressure ≥140/90mmHg. It is an important treatable risk factor for cardiovascular disease, with a high prevalence in the general population. The most common cause, essential hypertension, is a widespread disease - however, secondary hypertension is under investigated and under diagnosed. Read More

    Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy in acromegalic patient with severe headache.
    Rom J Morphol Embryol 2016 ;57(3):1149-1153
    Department of Endocrinology, "Carol Davila" University of Medicine and Pharmacy, "C. I. Parhon" National Institute of Endocrinology, Bucharest, Romania;
    A 68-year-old female patient was admitted in our clinic with severe frontal bilateral headache, dizziness, depression and cognitive decline in the context of a previously diagnosed acromegaly. She also had high blood pressure, dyslipidemia, secondary diabetes mellitus. Acromegaly was caused by a growth hormone (GH) secreting-pituitary macroadenoma, so a transsphenoidal surgery was performed. Read More

    Impact of AIP and inhibitory G protein alpha 2 proteins on clinical features of sporadic GH-secreting pituitary adenomas.
    Eur J Endocrinol 2017 Feb;176(2):243-252
    Department of Medical and Clinical Genetics & Genome-Scale BiologyResearch Programs Unit, University of Helsinki, Helsinki, Finland
    Introduction: In sporadic acromegaly, downregulation of AIP protein of the adenomas associates with invasive tumor features and reduced responsiveness to somatostatin analogues. AIP is a regulator of Gai signaling, but it is not known how the biological function of the Gai pathway is controlled.

    Aim: To study GNAS and AIP mutation status, AIP and Gai-2 protein expressions, Ki-67 proliferation indices and clinical parameters in patients having primary surgery because of acromegaly at a single center between years 2000 and 2010. Read More

    Acromegaly, genetic variants of the aryl hydrocarbon receptor pathway and environmental burden.
    Mol Cell Endocrinol 2016 Dec 18. Epub 2016 Dec 18.
    Department of Clinical and Experimental Medicine - Endocrinology Unit, University of Messina, Italy. Electronic address:
    Increasing evidence suggests that environmental contaminants can exert endocrine disruptors activities and that pollution exposition can have a role in tumorigenic processes. Several environmental pollutants have been shown to affect pituitary cells biology and function. The aryl hydrocarbon receptor (AHR) pathway is involved in xenobiotics' metabolism and in tumorigenesis. Read More

    Management of aggressive growth hormone secreting pituitary adenomas.
    Pituitary 2016 Dec 16. Epub 2016 Dec 16.
    Division of Endocrinology, Department of Medicine, Keck School of Medicine of the University of Southern California, USC Pituitary Center, 1520 San Pablo Street #3800, Los Angeles, CA, 90033, USA.
    Aggressive GH-secreting pituitary adenomas (GHPAs) represent an important clinical problem in patients with acromegaly. Surgical therapy, although often the mainstay of treatment for GHPAs, is less effective in aggressive GHPAs due to their invasive and destructive growth patterns, and their proclivity for infrasellar invasion. Medical therapies for GHPAs, including somatostatin analogues and GH receptor antagonists, are becoming increasingly important adjuncts to surgical intervention. Read More

    Incidence and prevalence of clinically relevant pituitary adenomas: retrospective cohort study in a Health Management Organization in Buenos Aires, Argentina.
    Arch Endocrinol Metab 2016 Nov-Dec;60(6):554-561. Epub 2016 Aug 25.
    Research in Internal Medicine Unit, Department of Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
    Objectives: The main purpose of this study was to estimate the incidence rate and prevalence of clinically relevant pituitary adenomas (PAs) within the Hospital Italiano Medical Care Program (HIMCP), a well-defined population of 150,000 members living in the urban and suburban area of the city of Buenos Aires. We defined clinically relevant PAs as those associated with endocrine dysfunction and/or mass effect.

    Subjects And Methods: A retrospective open cohort study was conducted, including all members of the HIMCP over 18 years old, with active memberships during the period of the study, from January 1st 2003, to January 1, 2014. Read More

    1 OF 193